127 related articles for article (PubMed ID: 18577465)
1. Transient dimerization and interaction with ERGIC-53 occur in the fibroblast growth factor receptor 3 early secretory pathway.
Lievens PM; De Servi B; Garofalo S; Lunstrum GP; Horton WA; Liboi E
Int J Biochem Cell Biol; 2008; 40(11):2649-59. PubMed ID: 18577465
[TBL] [Abstract][Full Text] [Related]
2. Cell adaptation to activated FGFR3 includes Sprouty4 up regulation to inhibit the receptor-mediated ERKs activation from the endoplasmic reticulum.
Lievens PM; Zanolli E; Garofalo S; Liboi E
FEBS Lett; 2009 Oct; 583(19):3254-8. PubMed ID: 19761767
[TBL] [Abstract][Full Text] [Related]
3. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
Lievens PM; Liboi E
J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
[TBL] [Abstract][Full Text] [Related]
4. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways.
Lievens PM; Roncador A; Liboi E
J Mol Biol; 2006 Mar; 357(3):783-92. PubMed ID: 16476447
[TBL] [Abstract][Full Text] [Related]
5. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
[TBL] [Abstract][Full Text] [Related]
6. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
7. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
Adar R; Monsonego-Ornan E; David P; Yayon A
J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
[TBL] [Abstract][Full Text] [Related]
8. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
Khnykin D; Olsnes S
Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
[TBL] [Abstract][Full Text] [Related]
9. Effect of pathogenic cysteine mutations on FGFR3 transmembrane domain dimerization in detergents and lipid bilayers.
You M; Spangler J; Li E; Han X; Ghosh P; Hristova K
Biochemistry; 2007 Oct; 46(39):11039-46. PubMed ID: 17845056
[TBL] [Abstract][Full Text] [Related]
10. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1.
Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H
Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467
[TBL] [Abstract][Full Text] [Related]
11. The localization of FGFR3 mutations causing thanatophoric dysplasia type I differentially affects phosphorylation, processing and ubiquitylation of the receptor.
Bonaventure J; Horne WC; Baron R
FEBS J; 2007 Jun; 274(12):3078-93. PubMed ID: 17509076
[TBL] [Abstract][Full Text] [Related]
12. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I.
d'Avis PY; Robertson SC; Meyer AN; Bardwell WM; Webster MK; Donoghue DJ
Cell Growth Differ; 1998 Jan; 9(1):71-8. PubMed ID: 9438390
[TBL] [Abstract][Full Text] [Related]
14. Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Förster resonance energy transfer.
Sarabipour S; Del Piccolo N; Hristova K
Acc Chem Res; 2015 Aug; 48(8):2262-9. PubMed ID: 26244699
[TBL] [Abstract][Full Text] [Related]
15. A central nervous system specific mouse model for thanatophoric dysplasia type II.
Lin T; Sandusky SB; Xue H; Fishbein KW; Spencer RG; Rao MS; Francomano CA
Hum Mol Genet; 2003 Nov; 12(21):2863-71. PubMed ID: 12966031
[TBL] [Abstract][Full Text] [Related]
16. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
Del Piccolo N; Placone J; Hristova K
Biophys J; 2015 Jan; 108(2):272-8. PubMed ID: 25606676
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations.
Cormier S; Delezoide AL; Benoist-Lasselin C; Legeai-Mallet L; Bonaventure J; Silve C
Am J Pathol; 2002 Oct; 161(4):1325-35. PubMed ID: 12368206
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Mac-2BP secretion is mediated by its N-glycan binding to ERGIC-53.
Chen Y; Hojo S; Matsumoto N; Yamamoto K
Glycobiology; 2013 Jul; 23(7):904-16. PubMed ID: 23550150
[TBL] [Abstract][Full Text] [Related]
19. Cargo selectivity of the ERGIC-53/MCFD2 transport receptor complex.
Nyfeler B; Zhang B; Ginsburg D; Kaufman RJ; Hauri HP
Traffic; 2006 Nov; 7(11):1473-81. PubMed ID: 17010120
[TBL] [Abstract][Full Text] [Related]
20. FGFR3 mutation in thanatophoric dysplasia type 1 with bilateral cystic renal dysplasia: coincidence or a new association?
Prontera P; Sensi A; Pilu G; Baldi M; Baffico M; Bonasoni R; Calzolari E
Genet Couns; 2006; 17(4):407-12. PubMed ID: 17375526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
